Entheon Biomedical Corp. Announces Participation in the Q2 Virtual Investor Summit

Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit.

 Event Q2 Investor Summit
 Date May 17-18th, 2021
 Presentation May 17th at 10:15 AM ET
 Location https://zoom.us/webinar/register/WN_qt5qaIR9SyODcSgsjZOfqw

About Entheon Biomedical Corp.

Entheon Biomedical is a drug development and biotechnology company whose primary aim is to provide solutions for people battling addiction so they can reclaim their lives and potential. With a focus on advancing the therapeutic potential of the DMT molecule through clinical trials and a traditional regulatory framework, Entheon is also developing specialized tools to personalize care, from patient assessment to psychedelic treatment and beyond. Entheon believes a comprehensive and holistic approach to care will significantly increases the odds of permanent recovery for those struggling with addiction disorders.

For further information:

Entheon Biomedical Corp.
Joseph Cullen
+1(778) 919-8615

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q2 Investor Summit will take place virtually, featuring 80+ companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com


Sasha Murray at sasha@investorsummitgroup.com

About The Wall Street Analyzer 1501 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.